- Trials with a EudraCT protocol (648)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
648 result(s) found for: metabolic assessment.
Displaying page 7 of 33.
EudraCT Number: 2015-003873-13 | Sponsor Protocol Number: ESR-14-10613/D1690L00044 | Start Date*: 2016-02-25 | |||||||||||
Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders | |||||||||||||
Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy. | |||||||||||||
Medical condition: Diabetes mellitus type 2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002225-30 | Sponsor Protocol Number: 69HCL18_0957 | Start Date*: 2019-07-18 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study | ||||||||||||||||||
Medical condition: chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000620-28 | Sponsor Protocol Number: LPS14245 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002606-40 | Sponsor Protocol Number: CLCZ696B2207 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma Service AG | |||||||||||||
Full Title: A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects | |||||||||||||
Medical condition: Mild to moderate essential hypertension in obese subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000828-24 | Sponsor Protocol Number: ANRS163ETRAL | Start Date*: 2015-05-31 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with a... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002205-19 | Sponsor Protocol Number: INCB50465-202 | Start Date*: 2017-07-26 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed) FR (Completed) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002963-40 | Sponsor Protocol Number: IDAPADM1 | Start Date*: 2015-10-26 | |||||||||||
Sponsor Name:Dra Cristina Avendaño Sola | |||||||||||||
Full Title: Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000123-28 | Sponsor Protocol Number: IJB-MULTI-MIME-A-2017 | Start Date*: 2018-11-14 | |||||||||||||||||||||||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||||||||||||||||||||||
Full Title: Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial | |||||||||||||||||||||||||||||||||
Medical condition: esophageal ADC, esophageal SCC, Cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), or endometrial cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002107-15 | Sponsor Protocol Number: Kirby-MARCH | Start Date*: 2011-12-16 | |||||||||||
Sponsor Name:Kirby Institute, University of New South Wa | |||||||||||||
Full Title: Maraviroc Switch collaborative study A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcr... | |||||||||||||
Medical condition: Chronic HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004903-33 | Sponsor Protocol Number: IBM4809 | Start Date*: 2018-06-18 | |||||||||||
Sponsor Name:Orphazyme A/S | |||||||||||||
Full Title: Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis (sIBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000003-16 | Sponsor Protocol Number: UPBEAT-TIF | Start Date*: 2018-11-06 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Prevention of Gestational Diabetes in Obese Pregnant Women; a Proof of Principle Study Targeting Early Pregnancy Intervention to Women at Risk | |||||||||||||
Medical condition: Gestational diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006099-38 | Sponsor Protocol Number: P-piller102 | Start Date*: 2012-08-06 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study. | ||
Medical condition: Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inapprop... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004217-17 | Sponsor Protocol Number: CICL670AUS32 | Start Date*: 2011-12-09 | |||||||||||
Sponsor Name:Novartis Pharmaceuticals Corporation | |||||||||||||
Full Title: A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food | |||||||||||||
Medical condition: transfusional hemosiderosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018963-40 | Sponsor Protocol Number: CRO1498 | Start Date*: 2011-04-14 |
Sponsor Name:Imperial College London | ||
Full Title: A multi-centre, double-blind, individually randomised, placebo-controlled, parallel arm RCT with 12-week follow-up to establish the clinical and cost effectiveness of amisulpride augmentation of cl... | ||
Medical condition: Schizophrenia that has proved unresponsive to standard treatment and a subsequent trial of clozapine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003426-24 | Sponsor Protocol Number: CTU079G | Start Date*: 2013-02-13 |
Sponsor Name:Riemser Pharma GmbH | ||
Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b... | ||
Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m² | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006310-13 | Sponsor Protocol Number: CAO/ARO/AIO-12 | Start Date*: 2015-01-19 | ||||||||||||||||
Sponsor Name:University Hospital Frankfurt, Goethe University | ||||||||||||||||||
Full Title: CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: A randomized phase II trial of the German Rectal Cancer Study ... | ||||||||||||||||||
Medical condition: Locally advanced rectal cancer (UICC stage II and III) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004287-56 | Sponsor Protocol Number: CHUBX2016/44 | Start Date*: 2019-11-21 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study | |||||||||||||
Medical condition: rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004164-60 | Sponsor Protocol Number: CUV040 | Start Date*: 2022-05-19 |
Sponsor Name:CLINUVEL (UK) LTD | ||
Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease. | ||
Medical condition: Variegate Porphyria (VP)-related skin disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001987-31 | Sponsor Protocol Number: COMBAT_T2_NASH_002 | Start Date*: 2020-08-05 | |||||||||||
Sponsor Name:Deutsche Diabetes Forschungsgesellschaft e.V. | |||||||||||||
Full Title: COMBined Active Treatment in Type 2 Diabetes with NASH | |||||||||||||
Medical condition: Diabetes mellitus type 2 (T2D) and non-alcoholic steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006224-40 | Sponsor Protocol Number: AxGD | Start Date*: Information not available in EudraCT |
Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka" | ||
Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p... | ||
Medical condition: Gaucher disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
